Xeris Pharmaceuticals Inc (XERS) - Total Assets
Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) holds total assets worth $411.90 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xeris Pharmaceuticals Inc - Total Assets Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Xeris Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Xeris Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Xeris Pharmaceuticals Inc's total assets of $411.90 Million consist of 62.7% current assets and 37.3% non-current assets. Review Xeris Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.0% |
| Accounts Receivable | $51.05 Million | 13.3% |
| Inventory | $68.67 Million | 17.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $88.08 Million | 23.0% |
| Goodwill | $22.86 Million | 6.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See XERS stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xeris Pharmaceuticals Inc's current assets represent 62.7% of total assets in 2025, a decrease from 98.9% in 2016.
- Cash Position: Cash and equivalents constituted 29.0% of total assets in 2025, down from 96.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 23.0% of total assets.
Xeris Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Xeris Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Xeris Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.45 | 1.95 | 3.34 |
| Quick Ratio | 1.02 | 1.24 | 2.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $85.19 Million | $90.41 Million | $87.08 Million |
Xeris Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Xeris Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 107.68 |
| Latest Market Cap to Assets Ratio | 3.65 |
| Asset Growth Rate (YoY) | 18.7% |
| Total Assets | $383.53 Million |
| Market Capitalization | $1.40 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Xeris Pharmaceuticals Inc's assets at a significant premium (3.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Xeris Pharmaceuticals Inc's assets grew by 18.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual total assets of Xeris Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $383.53 Million | +18.72% |
| 2024-12-31 | $323.06 Million | +0.14% |
| 2023-12-31 | $322.60 Million | -6.36% |
| 2022-12-31 | $344.52 Million | +13.20% |
| 2021-12-31 | $304.36 Million | +179.26% |
| 2020-12-31 | $108.99 Million | 0.00% |
| 2019-12-31 | $108.99 Million | -9.20% |
| 2018-12-31 | $120.03 Million | +166.74% |
| 2017-12-31 | $45.00 Million | +34.19% |
| 2016-12-31 | $33.53 Million | -- |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more